Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Biotech Company Reveals Major Data From Acute Myeloid Leukemia Study

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress.
Bio-Path Holdings, Inc., a biotechnology company listed on NASDAQ under the ticker symbol BPTH, is leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs. On June 14, 2024, the company presented interim results from its ongoing Phase 2 study of prexigebersen (BP1001) in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). The presentation took place at the 2024 European Hematology Association (EHA) Congress in Madrid, Spain. $Bio-Path Holdings(BPTH.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
Translate
Report
1369 Views
Comment
Sign in to post a comment
    178Followers
    0Following
    400Visitors
    Follow